Tag Archives: NUS

Friday’s Highlights at Noon: Celldex (CLDX), Brainstorm Cell Therapeutics (BCLI), Inovio Pharmaceuticals (INO), Nu Skin (NUS), Pacira Pharmaceuticals (PCRX)

So far Friday, July 3, NASDAQ is down -2.97% and the S&P is down -2.01%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Celldex (CLDX – Research Report), Brainstorm Cell Therapeutics (BCLI –

Thursday’s Midday Stock Update: Celldex (CLDX), Inovio Pharmaceuticals (INO), Brainstorm Cell Therapeutics (BCLI), Aerie Pharma (AERI), Nu Skin (NUS)

So far Thursday, July 2, NASDAQ is down -0.04% and the S&P is down -0.1%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Celldex (CLDX – Research Report), Inovio Pharmaceuticals (INO – Research

Thursday’s Midday Movers: Ebix (EBIX), Omega Healthcare (OHI), Nu Skin (NUS), El Pollo LoCo (LOCO), Arrowhead Pharmaceuticals (ARWR)

So far Thursday, March 19, NASDAQ is up 12.04% and the S&P is up 3.46%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Ebix (EBIX – Research Report), Omega Healthcare (OHI – Research

Wednesday’s Highlights at Noon: Intercept Pharma (ICPT), LendingClub (LC), HP (HPQ), Nu Skin (NUS), Devon Energy (DVN)

So far Wednesday, November 6, NASDAQ is down -2.01% and the S&P is down -0.52%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Intercept Pharma (ICPT – Research Report), LendingClub (LC – Research

Nu Skin (NUS) Receives a Buy from Pivotal Research

In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on Nu Skin (NUS – Research Report), with a price target of $70. The company’s shares closed yesterday at $38.54, close to its 52-week low of

Pivotal Research Keeps a Buy Rating on Nu Skin (NUS)

Pivotal Research analyst Timothy Ramey reiterated a Buy rating on Nu Skin (NUS – Research Report) on March 8 and set a price target of $85. The company’s shares closed yesterday at $59.26, close to its 52-week low of $56.09.